Background and goals
Power hepatitis B (CHB) stays a big world well being problem, and efficient antiviral therapies are important for long-term administration. This research aimed to guage the real-world effectiveness and security of tenofovir amibufenamide (TMF) in a cohort of sufferers with power hepatitis B (CHB).
Strategies
On this multicenter, potential, real-world cohort research, 194 CHB sufferers have been recruited from 4 hospitals between August 2021 and August 2022. Sufferers have been divided into treatment-naïve (TN, n = 123) and treatment-experienced (TE, n = 71) teams. The TN group was additional subdivided into TMF (n = 63) and tenofovir disoproxil fumarate (TDF, n = 60) subgroups. Within the TE group, sufferers transitioned from prior antiviral therapies (entecavir or TDF) to TMF after assembly standards for poor virological response or security considerations. Remedy response was evaluated by way of virological effectiveness and alanine transaminase normalization charges. Virological response (VR), ALT normalization charges, renal perform markers, and lipid profiles have been monitored.
Outcomes
Within the TN cohort, VR charges at 24 and 48 weeks have been 42.86% and 90.48% for TMF, and 60.00% and 83.33% for TDF. ALT normalization charges at 24 and 48 weeks for TMF have been 56.82% and 70.45% (in response to AASLD 2018 requirements). Within the TE group, VR charges at 24 and 48 weeks have been 83.1% and 91.55%, respectively. ALT normalization charges have been 86.67% and 93.33% (native requirements), and 66.67% and 76.67% (AASLD 2018 requirements) (z = −2.822, P = 0.005). Moreover, TMF confirmed improved renal security over TDF, with no important variations in lipid concentrations.
Conclusions
TMF is similar to TDF by way of CHB remedy effectiveness, with higher renal security and no impression on lipid ranges. In TE sufferers, transitioning to TMF remedy doesn’t have an effect on antiviral remedy outcomes.
Supply:
Journal reference:
Li, Y., et al. (2025). Effectiveness and Security of Tenofovir Amibufenamide within the Remedy of Power Hepatitis B: A Actual-world, Multicenter Examine. Journal of Medical and Translational Hepatology. doi.org/10.14218/jcth.2024.00364.
